TAMI ORTON: Open Payments
NPI 1407452873 · LINCOLN, NE. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,486 in 146 payments from 17 companies in 2025. Trend: 2023 $1,171 · 2024 $3,051 · 2025 $2,486
Food & beverage: $2,486
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 39 | $529 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 23 | $409 |
| E.R. Squibb & Sons, L.L.C. | 16 | $252 |
| Axsome Therapeutics, Inc. | 8 | $249 |
| Teva Pharmaceuticals USA, Inc. | 13 | $234 |
| JAZZ PHARMACEUTICALS INC. | 10 | $174 |
| Otsuka America Pharmaceutical, Inc. | 12 | $165 |
| Janssen Pharmaceuticals, Inc | 8 | $141 |
| HARMONY BIOSCIENCES LLC | 3 | $79 |
| Neurocrine BioSciences, Inc. | 3 | $53 |
Products named: VRAYLAR, CAPLYTA, COBENFY, Auvelity, XYWAV, UZEDY, REXULTI, INVEGA SUSTENNA.
Industry payments across NE — which companies pay providers there.
